Sunday, 21 July 2019
Latest news
Main » At $75.72 Esperion Therapeutics, Inc. (ESPR) Forms Bullish Multiple Top Pattern

At $75.72 Esperion Therapeutics, Inc. (ESPR) Forms Bullish Multiple Top Pattern

16 April 2018

The stock increased 1.87% or $1.72 during the last trading session, reaching $93.58. About 41,600 shares traded. Since April 15, 2017 ESPR has risen 89.86% and is uptrending. (NASDAQ:ESPR). The New York-based Goldman Sachs Gp has invested 0.01% in Esperion Therapeutics, Inc. Meditor Group Ltd bought 27,900 shares as the company's stock rose 22.41% while stock markets declined.

Esperion Therapeutics, Inc is a pharmaceutical company. The stock increased 1.30% or $0.95 during the last trading session, reaching $74.26. ESPR has 369,096 shares volume. (NASDAQ:ESPR). Discovery Cap Management Limited Liability Company Ct stated it has 0.97% in Esperion Therapeutics, Inc. ESPR outperformed the S&P500 by 78.31%.

Sabby Management Llc, which manages about $835.79M and $1.08 billion US Long portfolio, decreased its stake in Amarin Corporation Plc (Call) by 10,232 shares to 2,418 shares, valued at $970,000 in 2017Q4, according to the filing.

"Buy" rating has 7, "Sell" are 0, while 4 are "Hold". Therefore 25% are positive. Esperion Therapeutics had 61 analyst reports since July 28, 2015 according to SRatingsIntel. RBC Capital Markets maintained Time Warner Inc. On Friday, January 5 the stock of Esperion Therapeutics, Inc. Citigroup maintained it with "Buy" rating and $22 target in Wednesday, June 29 report. The company now has a consensus rating of Buy and an average target price of $92.54. The firm has "Buy" rating by Cowen & Co given on Wednesday, October 18. Northland Capital maintained it with "Buy" rating and $72.0 target in Tuesday, October 3 report. The firm has "Buy" rating by Cowen & Co given on Tuesday, June 13. (NASDAQ:ESPR) earned "Neutral" rating by UBS on Wednesday, February 21. (NASDAQ:ESPR) with "Buy" rating. The firm earned "Buy" rating on Monday, January 15 by Stifel Nicolaus.

Investors sentiment increased to 0.94 in Q4 2017. During the same quarter last year, the business posted ($1.29) EPS. sell-side analysts expect that Esperion Therapeutics will post -5.61 earnings per share for the current year. Night Owl Cap Limited Liability Corporation owns 173,195 shares. (NASDAQ:ESPR) to report earnings on May, 3. Bancshares Of Montreal Can reported 7,596 shares. Swiss Fincl Bank reported 34,300 shares. Vestor Capital Ltd Liability Corp holds 3.09% or 167,245 shares. Morgan Stanley has invested 0% in Esperion Therapeutics, Inc. (NASDAQ:ESPR). Bancorp Of America Corp De accumulated 0% or 42,927 shares. Qs Invsts Limited Liability has 126,546 shares. Prelude Capital Mgmt Lc owns 500 shares or 0% of their United States portfolio. Credit Suisse Ag reported 1.02M shares stake. Hall Laurie J Trustee has 190 shares for 0.01% of their portfolio. OxFORD Asset Management LLP acquired a new position in Esperion Therapeutics during the 3rd quarter worth about $715,000. (NASDAQ:ESPR) to report earnings on May, 3.

Investors sentiment increased to 1.16 in 2017 Q4. Its up 0.05, from 1 in 2017Q3. 45 funds opened positions while 55 raised stakes. Moreover, C M Bidwell And Assoc has 0.25% invested in Visa Inc. (NASDAQ:ESPR). Principal Group holds 4,169 shares or 0% of its portfolio. (NASDAQ:ESPR). C World Grp Incorporated A S invested in 0% or 4,433 shares. (NYSE:TWX) or 1,683 shares. Jasper Ridge Partners LP reported 9,773 shares. Capital Guardian Co invested in 977,335 shares. 16,631 are held by Proshare Advisors Ltd Co. Following the completion of the sale, the director now directly owns 639,682 shares of the company's stock, valued at $46,293,786.34. Jones Companies Lllp reported 0.03% in Visa Inc. (NYSE:TWX) or 78,786 shares. (NASDAQ:ESPR). 230,000 were reported by Ghost Tree Cap Limited Company. Iguana Healthcare Management LLC boosted its stake in Esperion Therapeutics by 10.0% during the fourth quarter. (NYSE:V) to report earnings on April, 19. V's profit will be $2.28B for 29.89 P/E if the $1.01 EPS becomes a reality. After $0.51 actual EPS reported by Bruker Corporation for the previous quarter, Wall Street now forecasts -52.94% negative EPS growth.

In total 11 analysts cover Esperion (NASDAQ:ESPR). Therefore 73% are positive. Time Warner Inc. had 123 analyst reports since August 6, 2015 according to SRatingsIntel. The stock has "Strong Buy" rating by Needham on Monday, March 20. The company was maintained on Friday, February 2 by BMO Capital Markets. JP Morgan has "Neutral" rating and $65 target. On Tuesday, November 21 the stock rating was maintained by Wells Fargo with "Hold". As per Thursday, March 17, the company rating was reinitiated by Oppenheimer. BB&T Securities LLC bought a new stake in Esperion Therapeutics during the fourth quarter valued at $263,000. Chardan Capital Markets has "Neutral" rating and $100 target. (NYSE:TWX) on Thursday, November 5 to "Market Perform" rating. SunTrust has "Buy" rating and $135 target.

Since December 14, 2017, it had 0 insider purchases, and 3 selling transactions for $2.88 million activity. $707,561 worth of Visa Inc.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.